Tetratherix Launches Precision Medicine Platform with $30M Partnership for Nasal Drug Delivery
核心洞察
Tetratherix (搜索) has launched a new precision medicine franchise using its Tetramatrix (搜索) platform polymer for nasal drug delivery, securing an exclusive partnership with US health group Superpower Health (搜索) worth up to $30 million over 10 years.
The STEPP (搜索) carrier system enables nasal delivery of complex therapeutic compounds including GLP-1 (搜索) peptides and hormones by forming a protective cushion in the nasal cavity that prevents degradation and allows controlled absorption into the bloodstream.
The technology has been under development for over five years in collaboration with major research institutions and has demonstrated effectiveness with various biological payloads including mRNA, antibiotics, antibodies, and growth factors.
Tetratherix (搜索) has launched a new precision medicine franchise built on its Tetramatrix (搜索) platform polymer, securing an exclusive research and development agreement with US consumer health group Superpower Health (搜索) worth up to $30 million over 10 years. The partnership focuses on developing nasal drug delivery technologies that could transform how complex biologic therapies are administered.
STEPP Technology Enables Nasal Delivery of Complex Compounds
The new precision medicine franchise introduces the STEPP (搜索) carrier system, which uses the Tetramatrix (搜索) polymer to enable nasal delivery of complex therapeutic compounds including glucagon-like peptide-1 (GLP-1 (搜索)), peptides, and hormones for the US market. The STEPP system forms a protective and adhesive cushion on the lining of the nasal cavity after administration, anchoring therapeutic compounds in place long enough for them to move into the bloodstream rather than being washed away by natural nasal processes.
This approach protects delicate molecules such as GLP-1 (搜索) and peptide therapies from degradation by enzymes within the nasal environment. By shielding these molecules and allowing controlled release into the bloodstream, the system aims to increase the amount of active compound reaching the body. Tetratherix (搜索) believes this method might allow complex biologic therapies to be delivered through a nasal spray rather than injections.
Five Years of Development with Major Research Institutions
The STEPP (搜索) technology has been under development for more than five years in collaboration with major research institutions in Australia and the US, including the Terasaki Research Institute (搜索), Ab-Initio (搜索), and the Woolcock Research Institute (搜索). During development, the company tested the platform with a range of biological payloads including mRNA, antibiotics, antibodies, proteins, peptides, and growth factors.
This work demonstrated that STEPP (搜索) can act as a proprietary smart carrier system designed to address stability challenges associated with modern biologic therapies, while also confirming the platform can both stabilize delicate molecules and anchor them within the nasal canal to allow controlled absorption.
Immediate Revenue Generation and Strategic Impact
Under the exclusive agreement, Superpower will pay Tetratherix (搜索) $3 million annually for up to 10 years while also purchasing the STEPP (搜索) polymer for product development. The agreement creates an immediately revenue-generating pathway that strengthens the company's cash position while leaving resources for existing development programs.
"The establishment of the precision medicine franchise will unlock and accelerate additional opportunities, and the execution of the Superpower agreement significantly expedites revenues from product commercialisation—a great result for the business and its shareholders," said CEO Will Knox. "We are shifting the paradigm from complex implant technologies to active, high-velocity delivery systems—ensuring our technology isn't just a part of the future of medicine but the engine that drives it."
Complementary to Existing Programs
The new franchise expands the reach of the company's core technology while complementing existing Tetramatrix (搜索) applications in bone regeneration, tissue spacing, and tissue healing. Tetratherix (搜索) confirmed all milestones outlined in its prospectus remain on track and the company continues to expect two US Food and Drug Administration (搜索) approvals in its bone regeneration franchise in mid-calendar year 2026.
Chief technology officer Ali Fathi described the technology as representing the culmination of the company's "relentless, focused R&D in drug delivery—a journey driven by the conviction that science is only as powerful as its accessibility." He added, "We are now poised to transform the lives of millions across the globe."
The market responded positively to the announcement, with Tetratherix (搜索) shares surging 36% to $5.64 in morning trade, bringing year-to-date gains to 70.9%.